false 0001527753 0001527753 2022-03-23 2022-03-23












Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 23, 2022



Personalis, Inc.

(Exact name of Registrant as Specified in Its Charter)




Delaware   001-38943   27-5411038

(State or Other Jurisdiction

of Incorporation)



File Number)


(IRS Employer

Identification No.)


1330 O’Brien Drive  
Menlo Park, California 94025   94025
(Address of Principal Executive Offices)   (Zip Code)

(650) 752-1300

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):



Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   PSNL   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 23, 2022, Jonathan MacQuitty, Ph.D., a director of Personalis, Inc. (the “Company”), notified the Company’s Board of Directors (the “Board”) of his decision not to stand for reelection following the end of his current term on May 17, 2022. Dr. MacQuitty served as an independent member of the Board since June 2011 and as Chair of the Board since 2019. Dr. MacQuitty also served as Chair of the Company’s Compensation Committee. Dr. MacQuitty indicated that his decision not to stand for re-election was not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

The Board appointed Karin Eastham to serve as the Chair of the Board following Dr. MacQuitty’s term, effective as of May 17, 2022.

The Board also appointed Olivia Bloom to serve as Chair of the Audit Committee of the Board and Blaine Bowman to serve as Chair of the Compensation Committee of the Board, each effective as of May 17, 2022.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits




99.1    Press release of Personalis, Inc., dated March 24, 2022
104    Cover Page Interactive Data File (embedded within the inline XBRL document).


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Date: March 24, 2022     Personalis, Inc.

/s/ Aaron Tachibana

      Aaron Tachibana
      Chief Financial Officer

Exhibit 99.1

Diagnostic Industry Veteran Karin Eastham to Chair Personalis Board of Directors

Personalis’ oncology diagnostics business expected to build on foundation of advanced technology already the driver of rapidly growing revenue from pharmaceutical companies

MENLO PARK, Calif.—(BUSINESS WIRE)—Mar. 24, 2022–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that Karin Eastham has been appointed as Personalis’ new Board Chair effective as of Personalis’ Annual Meeting of Stockholders on May 17, 2022. Ms. Eastham joined the Personalis Board in 2019 and has chaired both its Audit and Nominating and Corporate Governance Committees. Ms. Eastham earlier served on the Illumina Board, from 2004 to 2019. During that time Illumina acquired Solexa and became the world leader in DNA sequencing, and also launched multiple initiatives enabling its customers to leverage the technology in diagnostics, including oncology, NIPT, infectious disease and numerous inherited genetic conditions. Since 2012, Ms. Eastham has also served on the board of Veracyte, an advanced genomic diagnostic company. During that time, Veracyte’s annual revenue has grown from approximately $11.6 million to over $200 million.

“I am honored to be selected as Personalis’ next Board Chair at this exciting time in the company’s growth,” said Ms. Eastham. “I look forward to working closely with my fellow Board members and the company’s management team to help achieve Personalis’ vision of pharma and diagnostics businesses benefitting synergistically from a common base of increasingly advanced technologies.”

“Karin’s extensive leadership and operating experience, and her proven track record as a director of public life sciences companies, with particular focus on cancer patients, uniquely position her to serve as Personalis’ next Board Chair,” said John West, CEO and co-founder. “That background will be particularly relevant to Personalis as we build our oncology diagnostic business.”

Jonathan MacQuitty, Ph.D., who led the initiative for this transition, has decided not to stand for re-election at the upcoming Annual Meeting. “It has been an honor to serve as Chair of the Personalis Board,” said Dr. MacQuitty. “I am incredibly proud of the technology and IP that Personalis has developed over the past 11 years, particularly in neoantigen-based biomarkers for immuno-oncology, and its technology leadership in tumor-informed cancer monitoring. These have led to a substantial and rapidly growing business with leading oncology-focused pharmaceutical companies. We have understood for some time that this advanced technology could also serve as the base for an additional business in diagnostics. That was part of my motivation for helping to recruit Karin to our Board in 2019. In the intervening three years, she has come to know the management team well and she supports the team’s increasing emphasis on building a second, diagnostic-focused business. I have recommended that the Chair role now transition to a Board member with strong NGS-diagnostic business experience. I will continue to support the company from an outside strategic advisor role and look forward to its continued success.”

“It has been a privilege to work closely with Jonathan since founding Personalis over a decade ago,” said Mr. West. “On behalf of our Board, the company and shareholders, and personally, I would like to thank Jonathan for the invaluable contributions he has made as Chair, from the company’s founding to the present. I look forward to his ongoing involvement and support.”

Also effective as of the company’s Annual Meeting, the Personalis Board appointed Olivia Bloom to serve as Chair of the Audit Committee of the Personalis Board and Blaine Bowman to serve as Chair of the Compensation Committee of the Personalis Board. Ms. Eastham will continue to serve as Chair of the Nominating and Corporate Governance Committee in addition to her new role as Board Chair.

About Personalis

Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis’ Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit the Personalis website and follow Personalis on LinkedIn and Twitter.

Forward-Looking Statements

All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the NeXT Platform, Personalis’ business opportunities, leadership, mission, vision, plans or expectations, or other future events. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including Personalis’ most recent reports on Forms 8-K, 10-K and 10-Q, the company’s registration statement on Form S-3 filed on December 30, 2020, and the company’s prospectus supplement filed on January 3, 2022, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.

Investor Relations Contact for Personalis:

Caroline Corner





Media Contact for Personalis:

Jennifer Temple